对雄激素依赖性疾病的药物设计和药物发现的最新进展

Title:Recent Advances in Drug Design and Drug Discovery for Androgen- Dependent Diseases

Volume: 23 Issue: 8

Author(s): Marisa Cabeza, Araceli Sánchez-Márquez, Mariana Garrido, Aylín Silva and Eugene Bratoeff

Affiliation:

关键词: 良性前列腺增生，前列腺癌，5-α还原酶，17β-羟基类固醇脱氢酶，蛋白激酶A，雄激素受体，脱氢表雄酮衍生物，非渗透性睾酮结合物，G蛋白，蛋白激酶A

摘要: This article summarizes the importance of different targets such as 5α-reductase, 17β-HSD, CYP17A, androgen receptor and protein kinase A for the treatment of prostate cancer and benign prostatic hyperplasia. It is a well known fact that dihydrotestosterone (DHT) is associated with the development of androgen-dependent afflictions. At the present time, several research groups are attempting to develop new steroidal and non-steroidal molecules with the purpose of inhibiting the synthesis and biological response of DHT. This review also discusses the most recent studies reported in the literature that describe the therapeutic potential of novel compounds, as well as the new drugs, principally inhibitors of 5α-reductase.

Cite this article as:

Marisa Cabeza, Araceli Sánchez-Márquez, Mariana Garrido, Aylín Silva and Eugene Bratoeff , Recent Advances in Drug Design and Drug Discovery for Androgen- Dependent Diseases, Current Medicinal Chemistry 2016; 23 (8) . https://dx.doi.org/10.2174/0929867323666160210125642